These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 11523241)
41. Time- and rate-dependent alterations of the QT interval precede the onset of torsade de pointes in patients with acquired QT prolongation. Gilmour RF; Riccio ML; Locati EH; Maison-Blanche P; Coumel P; Schwartz PJ J Am Coll Cardiol; 1997 Jul; 30(1):209-17. PubMed ID: 9207644 [TBL] [Abstract][Full Text] [Related]
42. Hands-on help Torsades de pointes. Dulak SB RN; 2004 Oct; 67(10):24ac1-4. PubMed ID: 15552376 [TBL] [Abstract][Full Text] [Related]
43. Antiarrhythmic drugs and torsade de pointes. Lazzara R Eur Heart J; 1993 Nov; 14 Suppl H():88-92. PubMed ID: 8293758 [TBL] [Abstract][Full Text] [Related]
44. Ibutilide-induced long QT syndrome and torsade de pointes. Gowda RM; Punukollu G; Khan IA; Patlola RR; Tejani FH; Cosme-Thormann BF; Vasavada BC; Sacchi TJ Am J Ther; 2002; 9(6):527-9. PubMed ID: 12424513 [TBL] [Abstract][Full Text] [Related]
45. Safety of non-antiarrhythmic drugs that prolong the QT interval or induce torsade de pointes: an overview. De Ponti F; Poluzzi E; Cavalli A; Recanatini M; Montanaro N Drug Saf; 2002; 25(4):263-86. PubMed ID: 11994029 [TBL] [Abstract][Full Text] [Related]
46. QT interval prolongation and torsade de pointes. Patanè S; Marte F; Di Bella G Int J Cardiol; 2009 Jan; 131(2):e51-3. PubMed ID: 17689729 [TBL] [Abstract][Full Text] [Related]
47. A type 2 ryanodine receptor variant associated with reduced Ca Fujii Y; Itoh H; Ohno S; Murayama T; Kurebayashi N; Aoki H; Blancard M; Nakagawa Y; Yamamoto S; Matsui Y; Ichikawa M; Sonoda K; Ozawa T; Ohkubo K; Watanabe I; Guicheney P; Horie M Heart Rhythm; 2017 Jan; 14(1):98-107. PubMed ID: 27756708 [TBL] [Abstract][Full Text] [Related]
48. Electrophysiologic mechanisms of the long QT interval syndromes and torsade de pointes. Tan HL; Hou CJ; Lauer MR; Sung RJ Ann Intern Med; 1995 May; 122(9):701-14. PubMed ID: 7702233 [TBL] [Abstract][Full Text] [Related]
49. Pentavalent antimonial-induced torsade de pointes. Ortega-Carnicer J; Alcázar R; De la Torre M; Benezet J J Electrocardiol; 1997 Apr; 30(2):143-5. PubMed ID: 9141610 [TBL] [Abstract][Full Text] [Related]
50. Monotherapy versus combination therapy with class III antiarrhythmic agents to attenuate transmural dispersion of repolarization: a potential risk factor for torsade de pointes. Shah SA; Kluger J; White CM Pharmacotherapy; 2007 Sep; 27(9):1297-305. PubMed ID: 17723083 [TBL] [Abstract][Full Text] [Related]
51. A review of erythromycin-induced malignant tachyarrhythmia--torsade de pointes. A case report. Katapadi K; Kostandy G; Katapadi M; Hussain KM; Schifter D Angiology; 1997 Sep; 48(9):821-6. PubMed ID: 9313632 [TBL] [Abstract][Full Text] [Related]
52. Torsade de pointes: the clinical considerations. Gowda RM; Khan IA; Wilbur SL; Vasavada BC; Sacchi TJ Int J Cardiol; 2004 Jul; 96(1):1-6. PubMed ID: 15203254 [TBL] [Abstract][Full Text] [Related]
53. Mexiletine antagonizes effects of sotalol on QT interval duration and its proarrhythmic effects in a canine model of torsade de pointes. Chézalviel-Guilbert F; Davy JM; Poirier JM; Weissenburger J J Am Coll Cardiol; 1995 Sep; 26(3):787-92. PubMed ID: 7642874 [TBL] [Abstract][Full Text] [Related]
54. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. Makkar RR; Fromm BS; Steinman RT; Meissner MD; Lehmann MH JAMA; 1993 Dec; 270(21):2590-7. PubMed ID: 8230644 [TBL] [Abstract][Full Text] [Related]
56. Mode of onset of torsade de pointes in congenital long QT syndrome. Viskin S; Alla SR; Barron HV; Heller K; Saxon L; Kitzis I; Hare GF; Wong MJ; Lesh MD; Scheinman MM J Am Coll Cardiol; 1996 Nov; 28(5):1262-8. PubMed ID: 8890825 [TBL] [Abstract][Full Text] [Related]